Literature DB >> 8675327

Passive transfer of poly-(1-6)-beta-glucotriosyl-(1-3)-beta-glucopyranose glucan protection against lethal infection in an animal model of intra-abdominal sepsis.

R L Cisneros1, F C Gibson, A O Tzianabos.   

Abstract

Previous studies have established the efficacy of soluble polymers of poly-(1-6)-beta-glucotriosyl-(1-3)-beta-glucopyranose (PGG) glucan, a biological-response modifier, in protecting against mortality associated with experimentally induced peritonitis in a rat model. PGG glucan-treated animals showed increases in total leukocyte counts and enhanced bacterial clearance from blood. To further explore the mechanisms) by which this agent confers protection, studies were performed to examine whether protection could be transferred from PGG glucan-treated animals to naive recipients via spleen cells (SC), SC lysates, or serum. Passive-transfer experiments indicated that the responsible factor(s) was transferable by whole SC and SC lysates, as well as by peripheral leukocytes or serum from animals treated with PGG glucan. The transferable factor(s) was resistant to pronase and trypsin digestion, was heat stable at 56 or 80 degrees C, and was not removed by NH4SO4 precipitation. The protective effect of PGG glucan was abrogated by treatment with indomethacin, a potent inhibitor of prostaglandin synthesis. Administration of a purified prostaglandin extract from the sera of PGG glucan-treated animals protected against mortality in the peritonitis model. Furthermore, treatment of rats with exogenous synthetic prostaglandin E2 also conferred protection against mortality. These results suggest that the protective effect exhibited by PGG glucan in the rat peritonitis model is mediated, at least in part, by prostaglandins.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8675327      PMCID: PMC174056          DOI: 10.1128/iai.64.6.2201-2205.1996

Source DB:  PubMed          Journal:  Infect Immun        ISSN: 0019-9567            Impact factor:   3.441


  13 in total

1.  Identification of a reticuloendothelial stimulating agent in zymosan.

Authors:  S J RIGGI; N R DI LUZIO
Journal:  Am J Physiol       Date:  1961-02

2.  A beta-glucan inhibitable receptor on human monocytes: its identity with the phagocytic receptor for particulate activators of the alternative complement pathway.

Authors:  J K Czop; K F Austen
Journal:  J Immunol       Date:  1985-04       Impact factor: 5.422

3.  Antigenic specificity of opsonophagocytic antibodies in rabbit anti-sera to group B streptococci.

Authors:  R S Baltimore; D L Kasper; C J Baker; D K Goroff
Journal:  J Immunol       Date:  1977-02       Impact factor: 5.422

4.  Effect of prostaglandin E in multiple experimental models. VII. Effect on resistance to sepsis.

Authors:  J P Waymack; R F Guzman; A D Mason; B A Pruitt
Journal:  Burns       Date:  1990-02       Impact factor: 2.744

5.  Candida albicans stimulates arachidonic acid liberation from alveolar macrophages through alpha-mannan and beta-glucan cell wall components.

Authors:  M Castro; N V Ralston; T I Morgenthaler; M S Rohrbach; A H Limper
Journal:  Infect Immun       Date:  1994-08       Impact factor: 3.441

6.  Anti-infective effect of poly-beta 1-6-glucotriosyl-beta 1-3-glucopyranose glucan in vivo.

Authors:  A B Onderdonk; R L Cisneros; P Hinkson; G Ostroff
Journal:  Infect Immun       Date:  1992-04       Impact factor: 3.441

7.  Evidence for T cell-dependent immunity to Bacteroides fragilis in an intraabdominal abscess model.

Authors:  A B Onderdonk; R B Markham; D F Zaleznik; R L Cisneros; D L Kasper
Journal:  J Clin Invest       Date:  1982-01       Impact factor: 14.808

8.  Rapid extraction of oxygenated metabolites of arachidonic acid from biological samples using octadecylsilyl silica.

Authors:  W S Powell
Journal:  Prostaglandins       Date:  1980-11

9.  Experimental intra-abdominal abscesses in rats: development of an experimental model.

Authors:  W M Weinstein; A B Onderdonk; J G Bartlett; S L Gorbach
Journal:  Infect Immun       Date:  1974-12       Impact factor: 3.441

10.  Experimental intra-abdominal abscesses in rats: quantitative bacteriology of infected animals.

Authors:  A B Onderdonk; W M Weinstein; N M Sullivan; J G Bartlett; S L Gorbach
Journal:  Infect Immun       Date:  1974-12       Impact factor: 3.441

View more
  9 in total

Review 1.  Polysaccharide immunomodulators as therapeutic agents: structural aspects and biologic function.

Authors:  A O Tzianabos
Journal:  Clin Microbiol Rev       Date:  2000-10       Impact factor: 26.132

2.  Anticlastogenic effect of β-glucan, extracted from Saccharomyces cerevisiae, on cultured cells exposed to ultraviolet radiation.

Authors:  Ariane Fernanda da Silva; Rodrigo Juliano Oliveira; Andressa Megumi Niwa; Gláucia Fernanda Rocha D'Epiro; Lúcia Regina Ribeiro; Mário Sérgio Mantovani
Journal:  Cytotechnology       Date:  2012-06-09       Impact factor: 2.058

3.  Modulation of endotoxin- and enterotoxin-induced cytokine release by in vivo treatment with beta-(1,6)-branched beta-(1,3)-glucan.

Authors:  J Soltys; M T Quinn
Journal:  Infect Immun       Date:  1999-01       Impact factor: 3.441

4.  Synergism between poly-(1-6)-beta-D-glucopyranosyl-(1-3)-beta-D-glucopyranose glucan and cefazolin in prophylaxis of staphylococcal wound infection in a guinea pig model.

Authors:  A B Kaiser; D S Kernodle
Journal:  Antimicrob Agents Chemother       Date:  1998-09       Impact factor: 5.191

5.  Prophylactic anti-infective activity of poly-[1-6]-beta-D-glucopyranosyl-[1-3]-beta-D-glucopryanose glucan in a guinea pig model of staphylococcal wound infection.

Authors:  D S Kernodle; H Gates; A B Kaiser
Journal:  Antimicrob Agents Chemother       Date:  1998-03       Impact factor: 5.191

6.  Improved antimicrobial host defense in mice following poly-(1,6)-β-D-glucopyranosyl-(1,3)-β-D-glucopyranose glucan treatment by a gender-dependent immune mechanism.

Authors:  Courtni T Newsome; Estefany Flores; Alfred Ayala; Stephen Gregory; Jonathan S Reichner
Journal:  Clin Vaccine Immunol       Date:  2011-10-05

7.  Mesenchymal stem cell therapy promotes the improvement and recovery of renal function in a preclinical model.

Authors:  Antônio Urt-Filho; Rodrigo Juliano Oliveira; Larissa Correa Hermeto; João Renato Pesarini; Natan de David; Wilson de Barros Cantero; Gustavo Falcão; Guido Marks; Andréia Conceição Milan Brochado Antoniolli-Silva
Journal:  Genet Mol Biol       Date:  2016-06-03       Impact factor: 1.771

Review 8.  β-Glucan Metabolic and Immunomodulatory Properties and Potential for Clinical Application.

Authors:  Emma J Murphy; Emanuele Rezoagli; Ian Major; Neil J Rowan; John G Laffey
Journal:  J Fungi (Basel)       Date:  2020-12-10

9.  In vivo evaluation of the antimutagenic and antigenotoxic effects of β-glucan extracted from Saccharomyces cerevisiae in acute treatment with multiple doses.

Authors:  Rodrigo Juliano Oliveira; Maria José Sparça Salles; Ariane Fernanda da Silva; Tatiane Yumi Nakamura Kanno; Ana Carolina Dos Santos Lourenço; Véssia da Silva Leite; Hevenilton José Matiazi; João Renato Pesarini; Lúcia Regina Ribeiro; Mário Sérgio Mantovani
Journal:  Genet Mol Biol       Date:  2013-07-19       Impact factor: 1.771

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.